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ABSTRACT 
Background: Chronic alcohol misuse causes damage in the central nervous system that may lead to 
tolerance, craving and dependence. These behavioural changes are likely the result of cellular 
adaptations that include changes in gene expression. α-Synuclein is involved in the dopaminergic 
reward pathway, where it regulates dopamine synthesis and release. Previous studies have found 
that the gene for α-synuclein, SNCA, is differentially expressed in alcohol misusers.  Methods: The 
present study measured the expression of three α-synuclein variants, SNCA-140, SNCA-112, and 
SNCA-115 in the prefrontal cortex of controls and alcohol misusers with and without cirrhosis of 
the liver. In addition, eight SNPs located in the 5'- and 3'-UTRs were genotyped in a Caucasian 
population of 125 controls and 115 alcohol misusers. Results: The expression of SNCA-140 and 
SNCA-112 was significantly lower in alcohol misusers with cirrhosis than in controls. However, 
SNCA-115 expression was significantly greater in alcohol misusers with cirrhosis than in controls. 
Allele and genotype frequencies differed significantly between alcohol misusers and controls for 
three SNPs, rs356221, rs356219 and rs2736995. Two SNPs, rs356221 and rs356219, were in high 
linkage disequilibrium. There was no increased risk of alcoholism associated with specific 
genotypes or haplotypes. Our results suggest that the rs356219/356221 G-A haplotype may 
decrease the chance of having an alcohol misuse phenotype. Conclusion: These findings suggest 
that alcohol misuse may alter the expression of the individual α-synuclein splice variants differently 
in human brain. There was no evidence of an effect of sequence variation on the expression of α-
synuclein splice variants in this population. 
KEYWORDS: haplotype; human; prefrontal cortex; SNCA, variants, 3'-UTR 
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1. INTRODUCTION 
 Alcohol misuse results in a significant burden of disease in Australia and throughout the 
world. This is commonly attributed to the effects of alcohol on the brain and liver, resulting in brain 
damage and liver cirrhosis respectively (Crews et al., 2005). However, alcohol affects all organs of 
the body and is associated with an increased incidence of some types of cancers, greater 
susceptibility to inflammatory diseases, and difficulties with wound and bone healing (Miranda et 
al., 2010). The mechanism by which alcohol causes such diverse effects is not well understood. 
 In the brain, chronic alcohol misuse results in persistent changes in function that are 
manifested as tolerance, physical dependence, craving, and other behavioural changes (Nestler and 
Aghajanian, 1997). The changes in brain function originate from alterations in gene expression that, 
in turn, underlie the cellular adaption to chronic alcohol misuse (Anni and Israel, 2002; Nestler, 
2000). We and others have used whole-genome microarrays to delineate genes with altered 
expression in the brain following long-term alcohol consumption (Lewohl et al., 2000; Liu et al., 
2004, 2006; Mayfield et al., 2002), as well as the potentially confounding effects of concomitant 
diseases such as liver cirrhosis (Liu et al., 2007). The studies have identified genes that likely 
underlie the adaptive response of neurons in the prefrontal cortex, a brain region that is particularly 
susceptible to long-term alcohol misuse. These include genes involved in protein trafficking, 
myelination, ubiquitination, apoptosis, cell adhesion, neurogenesis, and neural disease. Studies 
using whole-genome microarrays (Lewohl et al., 2000; Liu et al., 2004, 2007, 2006; Mayfield et al., 
2002) and 2-D gel proteomics (Etheridge et al., 2009; Lewohl et al., 2004) have suggested that α-
synuclein is differentially regulated in the brain of alcohol misusers relative to controls. A recent 
study analysing data available from GWAS, animal and human genetic and gene expression studies 
found the α-synuclein gene (SNCA) to be the top candidate gene for alcoholism (Levey et al., 2014). 
 α-Synuclein mRNA exists in at least four distinct splice variants that produce functional 
polypeptides. These variants vary in their coding sequence as well as in the lengths of their 3'-
untranslated regions (3'-UTRs). The variants include the full-length (wild type) sequence comprised 
of 6 exons that encodes a 140 amino acid protein. Three shorter exon skipping variants include the 
126 amino acid variant, a transcript missing exon 3; the 112 amino acid variant, which is missing 
exon 5; and the 98 amino acid variant, where both exons 3 and 5 are absent. Although little is 
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known about the function of the polypeptides that arise from these individual splice variants, 
studies have shown that the variants exhibit distinct expression profiles in both healthy brain tissue 
and in neuropathological conditions such as Parkinson disease, Lewy body disease and Alzheimer 
disease (Beyer et al., 2008; Cardo et al., 2014). Additional splice variants are predicted in the 
Ensembl database, including one encoding a 115 amino acid variant (ENST00000502987) 
comprised of exons 1–4 and the first 393 nucleotides of intron 4. This variant thus contains a unique 
3'-UTR regulatory region however it is not known if any of these predicted splice variants produce 
functional polypeptides.  
 Studies measuring the expression levels of α-synuclein in the prefrontal cortex of human 
alcohol misusers have shown conflicting findings: some studies show lower expression in this brain 
region (Etheridge et al., 2009, Janeczek et al., 2012; Lewohl et al., 2004, 2000), and several 
additional studies show no difference in expression relative to controls (Liu et al., 2004, 2006; 
Mayfield et al., 2002). This is likely due to the fact that these studies did not measure the expression 
of individual splice variants.  
 SNCA contains a number of single nucleotide polymorphisms (SNPs) and microsatellite 
repeat regions throughout the gene. Of particular interest are those in the promoter region and 3'-
UTR that have the potential to influence expression of the gene. The SNCA-Rep1 region is a 
microsatellite repeat ~10 kb upstream of the translation start site. Variability in the length of this 
region has been associated with differences in expression. Specifically, there was a significantly 
higher frequency of the longer SNCA-Rep1 alleles in alcohol-dependent individuals that was 
correlated with higher α-synuclein expression in blood (Bonsch et al., 2005b), whereas we found a 
higher frequency of the shorter 267 bp allele in long-term alcohol misusers that was correlated with 
reduced expression of α-synuclein in the dorsolateral prefrontal cortex (Janeczek et al., 2012).  
 The 3'-UTR of SNCA is highly conserved across species (Sotiriou et al., 2009) and few of 
the SNPs identified in this region exhibit sufficient heterozygosity for further study. However, 
alcohol-use phenotypes have been associated with SNCA 3'-UTR polymorphisms. Specifically, a 
haplotype block consisting of six SNPs (rs2736990, rs356168, rs356200, rs7684318, rs356221 and 
rs356219) was over-transmitted to alcohol cravers and the complementary haplotype block was 
over-transmitted to non-cravers (Foroud et al., 2007). An additional SNP, rs2736995 was also found 
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to be associated with alcohol craving in this same study (Foroud et al., 2007). A study by Wilcox 
and colleagues found an association between SNPs in α-synuclein and alcohol-evoked taste cue 
(BOLD) responses in brain regions associated with craving (Wilcox et al., 2013). The SNPs 
rs356168, rs2301134 and rs2736990 were found to be associated with a greater BOLD response 
(Wilcox et al., 2013). Thus, a key question is whether genetic variation, particularly within the 3'-
UTR, affects the expression of α-synuclein. Here, we used real-time PCR to measure the expression 
of three splice variants, the two most-abundant variants, SNCA-140 and SNCA-112, as well as 
SNCA-115, a variant predicted to have a unique 3'-UTR, in the prefrontal cortex of alcohol misusers 
with and without cirrhosis of the liver and matched controls. A case-control approach was used to 
determine if a haplotype block in the SNCA 3'-UTR, along with other SNPs of interest, were 
associated with alcohol misuse. The approximate location of each of these SNPs in the SNCA gene 
is shown in Figure 1. We also investigated the influence of the SNCA 3'-UTR haplotype block on 
the expression of the gene. 
2. MATERIALS AND METHODS 
2.1 Tissue Samples 
 The Griffith University Human Ethics Committee provided ethical clearance for the project 
(MSC/02/06/HREC). The human brain tissue samples were collected by the Queensland Brain 
Bank, School of Chemistry and Molecular Biosciences, University of Queensland and the NSW 
Tissue Resource Centre, University of Sydney. Autopsied tissue samples were immersed in ~10 vol 
of 0.32 M sucrose and slowly frozen to best preserve the blocks (Dodd et al., 1986). The frozen 
samples were stored at –80oC until the RNA isolation outlined below. The region selected for 
analysis was the dorsolateral prefrontal cortex (Brodmann areas 6 and 8). 
2.2 Case Selection 
 For genotyping studies, DNA was extracted from 125 controls and 115 alcohol misusers. 
Subjects were classified by their daily average ethanol consumption in most of their adult life as 
reported in their medical records. Controls were those who consumed an average of <20 g of 
ethanol per day or were teetotalers; alcohol misusers were those who had a mean intake of >80 g of 
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ethanol per day (for 30 years on average). All cases were of European origin. No schizophrenic case 
was included.  
 Expression studies were performed on a subset of individuals for whom brain tissue was 
available. This cohort consisted of 61 individuals: 24 controls and 37 alcohol misusers. Alcohol 
misusers were further divided into those without comorbid disease (uncomplicated alcohol 
misusers, 25 cases) and those with pathologically confirmed cirrhosis of the liver (cirrhotic alcohol 
misusers, 12 cases). Alcohol misusers with cirrhosis of the liver generally have more severe brain 
damage compared to those without liver cirrhosis (Zahr et al., 2011). Damage to the liver due to 
long term alcohol misuse results in a higher effective dose reaching the brain, and greater 
neuropathological damage (Harper, 1998). In addition, the expression profile in the prefrontal 
cortex of alcohol misusers with cirrhosis of the liver is distinct from those without cirrhosis of the 
liver (Liu et al., 2007).  
 Cases and controls were matched as closely as possible for gender, age at death and post 
mortem interval (PMI). No subject suffered from any other known condition at the time of death, 
nor did they take psychoactive drugs or medications for psychiatric conditions. Individuals with 
Wernicke-Korsakoff syndrome, hepatic encephalopathy or any other neurological condition were 
excluded. The gender, age, PMI and brain weight of the cases in each group are detailed in Table 1. 
2.3 RNA Isolation and Reverse Transcription 
 TRIzol™ (Gibco BRL, Invitrogen, Mt Waverly, Victoria, Australia) was used to extract total 
RNA according to the manufacturer‟s instructions. The quantity of RNA attained was measured by 
absorbance at 260 nm using a Nanodrop device (Thermo Scientific, Waltham, MA, USA). RNA 
quality was determined by visual inspection of electropherograms produced by the Agilent 2100 
bio-analyzer (Palo lto, CA, USA). High quality total RNA samples produce distinct 18S and 28S 
ribosomal peaks and lack multiple peaks corresponding to smaller RNA fragments. Whereas, a 
decrease in 28S rRNA peak area, an increase in the baseline area below the 18S rRNA that spreads 
with smaller 28S rRNA fragments and a rise in the baseline between the 18S and 28S rRNA is 
indicative of a degraded sample. Degraded samples were excluded from further study. Total RNA 
was stored in aliquots of 20 µL that were reverse-transcribed into cDNA by previously established 
methods (Ho et al., 2010; MacKay et al., 2011), diluted 1/50, and stored at –80°C until required. 
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2.4 Primer Design 
 Primer Express® v1.5 Software (Applied Biosystems, Mulgrave, Vic, Australia) was used to 
design the primers, which were synthesized by Sigma-Aldrich P/L (Castle Hill, NSW, Australia). 
Each primer set was verified for specificity using the Basic Local Alignment Search Tool (BLAST) 
from the GenBank non-redundant nucleotide sequence database (Altschul et al., 1997). To eliminate 
gDNA amplification, all assays were designed such that at least one primer spanned an exon 
boundary. For the SNCA-115 variant, the primers included part of the sequence of intron 4. The 
primer sequences are shown in the supplementary Table S1
1
. The efficiency of each primer pair was 
determined using previously established methods (Pfaffl, 2001). 
2.5 Real-Time PCR 
 Real-time PCR was conducted on a 72 well rotor QIAGEN Rotor-Gene Q as previously 
described. In brief, each reaction contained 2 µL of 1/50 sample cDNA, 10 µL of Bio-Rad SYBR 
Green PCR Master Mix (Bio-Rad Laboratories Pty Ltd, Gladesville, NSW, Australia), 300 nM of 
each primer in a final reaction volume of 20 µL. Duplicate amplifications were performed for each 
sample. No-template controls were included for each primer pair. As in previous studies, 
glyceralderhyde-3-phosphate dehydrogenase (GAPDH) was used as the reference gene (Ho et al., 
2010; MacKay et al., 2011). The expression of GAPDH was not affected by disease state (Analysis 
of Variance (ANOVA): F2,62 = 0.932, P = 0.399). 
 The differences between the mean CT values of the duplicates for each variant and the 
endogenous control gene, GAPDH were calculated to give CT values used for statistical analysis. 
The relative quantitation value was then expressed as 2
−ΔC
T for presentation as outlined in previous 
studies (Ho et al., 2010; Livak and Schmittgen, 2001; MacKay et al., 2011). Statistical analysis was 
conducted using IBM SPSS Statistics 22 software (SPSS Inc, Chicago, IL, USA). ANOVA was 
followed, where appropriate, by the Tukey HSD post hoc tests. The effects of age at death, PMI and 
brain weight were determined using linear regression analysis. Where significant, covariance 
                                                 
1
 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:...  
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analysis (ANCOVA) was used to normalize that data and produce adjusted least-square mean and 
SEM values. 
2.6 DNA Extraction and Genotyping 
 Phenol/chloroform extraction followed by ethanol precipitation was used to extract gDNA 
from human brain tissue (Sambrook et al., 1989). Five of the eight SNPs were genotyped using the 
High Resolution Melt (HRM) method with the Qiagen Rotor-Gene Q System and two SNPs with 
the Corbett Rotor-Gene
™
 6000 Analyzer according to the manufacturer‟s instructions. 
 For the SNPs analysed on the Qiagen system, each reaction consisted of 20 ng of gDNA, 1 
Colourless GoTaq
®
 Flexi buffer, 2–3 mM of MgCl2, 400–800 µM of dNTPs (Promega, Annandale, 
NSW, Australia), forward and reverse primers (see Table S1
2
) at 300 nM, 1.5 µM SYTO
®
 9 green 
fluorescent nucleic acid stain (Invitrogen), 0.5 U of GoTaq
®
 Flexi Hot Start DNA Polymerase 
(Promega) in a final volume of 25 µl. Cycling conditions were: 95°C for 10 min, 95°C for 10 s, 
“annealing temperature” for 10 s, followed by an increase in temperature from 70°C to 80°C in 
increments of 0.1°C. Annealing temperatures for each primer pair can be found in the 
supplementary material provided online; Table S1
3
. Rotor-Gene Q Software was used to analyse the 
resultant melt curves. 
 The rs2301134 and rs2736990 SNPs were genotyped using the HRM method with the 
Corbett Rotor-Gene
™
 6000 as outlined in the HRM
™
 High Resolution Melt Assay Design and 
Analysis, CorProtocol
™
 (Corbett Life Science, Mortlake, NSW, Australia). For the SNPs analysed 
on the Corbett system, each reaction mixture contained 1 Colourless GoTaq® Flexi buffer, 0.5 U of 
GoTaq
®
 Flexi Hot Start DNA Polymerase, 3 µM MgCl2, 0.2 µM dNTPs (Promega), 1.5 µM of 
SYTO
®
 9 green fluorescent nucleic acid stain (Invitrogen), 0.3 µM of both forward and reverse 
primers and 40 ng of DNA in a final volume of 25 µl. Cycling conditions were: 95°C for 5 min, 
95°C for 5 s, 60°C for 10 s, followed by an increase in temperature from 70°C to 88°C in 
                                                 
2
 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:...  
 
3
 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:...  
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increments of 0.1°C. For each SNP, a representative sample of each genotype was sequenced to 
confirm that the correct product has been amplified. The samples were sequenced on an Applied 
Biosystems Hitachi ABI-3130 Genetic Analyzer. 
 Rs2736995 was genotyped using PCR-RFLP. The reaction mixture contained 0.2 µM each 
of the forward and reverse primers, 1 Colourless GoTaq® Flexi buffer, 2 mM MgCl2, 0.1 µM of 
dNTPs (Promega) and 20 ng of gDNA in a final volume of 25 µL. Cycling conditions were: 95°C 
for 10 min, then 40 cycles of 95°C for 30 s, 60°C for 30 s and 72°C for 30 s, followed by a final 
extension step of 72°C for 5 min. The PCR was performed using the Mastercycler
®
 ep gradient S 
(Eppendorf, North Ryde, NSW, Australia). The PCR product was digested using BtsCI restriction 
enzyme (New England Biolabs Inc. Genesearch P/L, Arundel, QLD, Australia). The final reaction 
volume of 15 µl contained 12U of BtsCI, 1 enzyme NEBuffer 4 (New England Biolabs Inc. 
Genesearch P/L), 7 µl of PCR product and was incubated at 65°C for 16 hours. The digested 
products were separated by agarose gel electrophoresis. 
2.7 Statistical Analyses 
 The allele and genotype frequencies for the eight SNPs were analysed using 2, odds-ratio 
and the Hardy-Weinberg Equilibrium (HWE) test. These tests were performed with the HWE and 
Association Testing for SNPs in Case-Control Studies DeFinetti program (http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl). The Haploview v4.2 (Barrett et al., 2005) program was used for Linkage 
Equilibrium (LD) analysis (D' and r
2
), haplotype prediction and case-control haplotype frequency 
comparison. The analysis includ d 2 tests with 10 000 permutations to correct for multiple testing 
bias. For SNPs that were found to have a significant difference in allele and genotype frequencies 
between alcohol misusers and controls based on χ2 analysis, we then looked closely at the 
frequencies (Table 3) to choose alleles that may increase or decrease the chance of an individual 
developing an alcohol misuse phenotype OR being in the control or alcohol misuser group. These 
would be defined as „risk‟ and „protective‟ alleles. To determine if any „risk‟ alleles/haplotypes 
identified from the frequency results predict higher odds of an individual having an alcohol misuse 
phenotype, each individual that had at least one copy of the „risk‟ allele/haplotype was assigned a 
value of 1 and all other samples were coded as 0. Logistic regression was then performed using 
IBM SPSS Statistics 22 software (SPSS Inc). The model was adjusted for sex, as initial analysis 
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showed correlations with the case/control variable (r = 0.188, P = 0.003). We then used the 
independent samples t-test (SPSS Inc) to investigate the effect of SNCA 3'-UTR haplotypes on α-
synuclein expression. We used the same method to determine if any „protective‟ alleles or 
haplotypes identified from the frequency results predicted decreased odds of an individual having 
an alcohol misuse phenotype. Differences were considered statistically significant at P < 0.05. 
3. RESULTS 
3.1 Expression Study 
 We measured the expression of the two most abundant α-synuclein transcripts, the wild type 
SNCA-140 variant, the shorter SNCA-112 variant, as well as the SNCA-115 variant, in the 
dorsolateral prefrontal cortex of chronic alcohol misusers and age- and sex-matched controls using 
real-time PCR.  
 Case information is outlined in Table 1. Alcohol misusers and controls were matched as 
closely as possible for PMI and age at death. There was no significant difference in age at death or 
PMI between the groups (Age: F2,58 = 2.243, P = 0.115; PMI: F2,58 = 0.408, P = 0.667). Overall, 
mean brain weights were significantly different across groups (F2,58 = 3.163, P = 0.05). Post hoc 
testing showed that brain weights of the cirrhotic alcohol misusers group were significantly lower 
than the uncomplicated alcohol misusers group (P = 0.05) but not when compared with controls (P 
= 0.088). To determine if the expression of any α-synuclein transcript was correlated with age at 
death, PMI, or brain weight, linear regression was performed on each parameter. Regression 
analysis was carried out using all subjects combined and with subjects separated according to 
alcohol status (controls vs. combined alcohol misusers).  
 Overall there was no significant correlation between the expression of any splice variant and 
age at death in combined subjects (Table 2), or for cases separated into their respective groups, with 
the exception of SNCA-115, which was significantly correlated with age at death in control subjects 
only (F1,22 = 7.447, P = 0.012). Inspection showed that the expression of SNCA-115 increased with 
age at death. There was no such correlation in combined alcohol misusers (F1,35 = 0.359, P = 
0.553). ANCOVA on the expression of SNCA-115 using age at death as the covariate did not alter 
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the pattern of effects observed with ANOVA alone. As the case groups did not differ significantly 
on age at death, a simple factorial ANOVA was appropriate to analyse the data. 
 There was no significant correlation between the expression of any splice variant and PMI 
for combined cases although this did approach significance for SNCA-115 (Table 2). There was also 
no significant correlation between the expression of any splice variant and PMI for cases separated 
into their respective groups, with the exception of SNCA-115, which was significantly correlated 
with PMI in combined alcohol misusers only (F1,35 = 5.134, P = 0.03). Inspection showed that the 
expression of SNCA-115 increased with longer PMIs. There was no such correlation in control 
subjects (F1,22 = 0.096, P = 0.759). ANCOVA on the expression of SNCA-115 with PMI as the 
covariate did not alter the pattern of effects observed with ANOVA alone. As the case groups did 
not differ significantly on PMI, a simple factorial ANOVA was appropriate to analyse the data. 
 The expression of each splice variant was significantly correlated with brain weight in 
combined subjects (Table 2). When case groups were analyzed separately, expression values for the 
SNCA-140 and SNCA-115 transcripts were significantly correlated with brain weight in combined 
alcohol misusers (SNCA-140: F1,35  = 5.151, P = 0.029; SNCA-115: F1,35 = 12.796, P = 0.001) but 
not in controls (SNCA-140: F1,22 = 4.709, P = 0.041; SNCA-115: F1,22 = 0.357, P = 0.557). There 
was no significant correlation with the SNCA-112 variant in combined alcohol misusers or controls 
(alcohol misusers: F1,35 = 3.086, P = 0.09; controls: F1,22 = 0.736, P = 0.40). Since the case groups 
differed significantly in brain weight we performed all statistical tests using both a simple factorial 
ANOVA and an ANCOVA with brain weight as the covariate. The same pattern of effects was 
observed in both analyses. 
 The expression of SNCA-140 (ANCOVA: F3,57 = 7.919, P < 0.001), SNCA-112 (ANCOVA: 
F3,57 = 2.801, P = 0.048), and SNCA-115 (ANCOVA: F3,57 = 6.062, P = 0.001) was significantly 
different between groups. The expression of the SNCA-140 transcript was significantly lower in 
cirrhotic alcohol misusers compared with both controls (Tukey HSD, P =0.001) and uncomplicated 
alcohol misusers (Tukey HSD, P = 0.003). The expression of the SNCA-112 variant was 
significantly lower in cirrhotic alcohol misusers compared with controls (Tukey HSD, P = 0.048) 
but not with uncomplicated alcohol misusers (Tukey HSD, P = 0.087). Conversely, the expression 
of the SNCA-115 variant was significantly greater in cirrhotic alcohol misusers compared with both 
† 
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controls (Tukey HSD, P = 0.008) and uncomplicated alcohol misusers (Tukey HSD, P = 0.012; 
Figure 2). 
3.2 Genotyping Study 
 To investigate the potential influence of polymorphisms in the SNCA 3'-UTR and elsewhere 
in the gene, we genotyped our population for the eight SNPs shown in Figure 1. Six of the eight 
SNPs (rs356221, rs356219, rs7684318, rs2736990, rs2736995 and rs2301134) were in HWE 
(P = 0.47, P = 0.46, P = 1.00, P = 1.00, P = 0.67 and P = 1.00 respectively); two (rs356168 and 
rs356200) were not (P = 0.018 and P = 0.011 respectively). 
 The allele and genotype frequencies differed significantly between alcohol misusers and 
controls for rs356221, rs356219 and rs2736995 (Table 3), where the T allele and TT genotype were 
more frequent in alcohol misusers than in controls for rs356221 and rs2736995, and the A allele and 
AA genotype were more frequent in alcohol misusers than in controls for rs356219. No significant 
difference was found between alcohol misusers and controls for the other SNPs (rs7684318, 
rs2736990, rs2301134, rs356168 and rs356200). A number of the SNPs in our study (rs2736990, 
rs356168, rs356200, rs7684318, rs356221 and rs356219) have previously been associated with 
alcohol craving as part of a 3'-UTR haplotype block (Foroud et al., 2007). Therefore, we performed 
further analysis to establish if this haplotype existed in our population. The Haploview program was 
used to calculate LD between all of the SNPs. Strong LD was found between rs356219 and 
rs356221 (D' = 0.949; r
2
 = 0.587; Figure 3). Haplotype analysis showed that the frequency of 
haplotype A-T was significantly lower in controls (Table 4), whereas a significantly lower 
frequency of haplotype G-A was seen in alcohol misusers. No significant difference was seen for 
the haplotype A-A. The frequency of the T-G haplotype in our population was less than 1% and 
therefore it was excluded from further analysis. Strong LD was also observed between rs356168 
and rs356221 (D′ = 0.98; r2 = 0.789; Figure 3), however as rs356168 did not follow HWE this 
result only provides weak support of a link between rs356168 and rs356221, and was therefore 
excluded from further analysis. 
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3.3 Determining Potential Risk and Protective Alleles and Haplotypes 
 The rs356219/rs356221 A and T alleles were identified as potential „risk‟ alleles for alcohol 
misuse due to their allele frequencies and, as mentioned previously, the haplotype A-T frequency 
was found to be significantly lower in controls (Table 4). However, logistic regression did not show 
that subjects with at least one copy of the rs356219 A allele and rs356221 T allele were more likely 
to have an alcohol misuse phenotype (adjusted odds ratio (ORadj) = 1.467, df = 1, P = 0.255, 95% 
confidence interval (CI) = 0.758–2.838). When examined separately, no increased risk was found 
for either allele (rs356219: ORadj = 1.992, df = 1, P = 0.114, 95% CI = 0.848–4.679; rs356221: 
ORadj = 1.426, df = 1, P = 0.282, 95% CI = 0.747–2.722). 
 The frequency of the rs2736995 T allele was significantly greater in alcohol misusers, and 
was therefore identified as a potential „risk‟ allele for alcohol misuse. We termed the T allele a „risk‟ 
allele to determine if individuals with at least one copy of the allele were more likely to be an 
alcohol misuser. However, these individuals were not significantly more likely to be an alcohol 
misuser (ORadj = 2.145, df = 1, P = 0.142, 95% CI = 0.775–5.935). 
 To determine if the 3'-UTR haplotype block previously identified by Foroud and colleagues 
(Foroud et al., 2007) was associated with alcohol misuse in our population, we constructed 
haplotypes in two ways by grouping individuals on the basis of whether they had a copy of the risk 
haplotype or not. The first approach involved using tag SNPs to represent all the haplotypes present 
in the haplotype block to estimate association with an alcohol misuse phenotype. As most of the 
SNPs genotyped in our study fell into Foroud‟s “block 3” (Foroud et al., 2007) we focused on the 
three tag SNPs that were significantly correlated with craving in that study. The second approach 
involved overlapping groups of three adjacent SNPs to form an extended haplotype. One of these 
haplotypes was over-transmitted to alcohol cravers (G-G-T-C-A-G, 10%) and its complementary 
haplotype (A-A-C-T-T-A, 50%) was over-transmitted to non-craving alcoholics (Foroud et al., 
2007). 
 Logistic regression showed that subjects with all three tag SNPs were not more likely to 
have an alcohol misuse phenotype (C-A-G: ORadj = 0.569, df = 1, P = 0.186, 95% CI = 0.247–
1.312; T-A-A: ORadj = 0.611, df = 1, P = 0.094, 95% CI = 0.343–1.088; T-T-A: ORadj = 1.327, 
df = 1, P = 0.424, 95% CI = 0.663–2.655). Furthermore, neither the extended haplotype over-
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transmitted to craving individuals, nor the haplotype over-transmitted to non-craving individuals 
was more likely to have an alcohol misuse phenotype (ORadj = 0.350, df = 1, P = 0.080, 95% CI = 
0.108–1.133; ORadj = 0.780, df = 1, P = 0.389, 95% CI = 0.443–1.372 respectively).  
 The rs356219/rs356221 G and A alleles were identified as potential „protective‟ alleles for 
alcohol misuse due to their allele frequencies. Also, as mentioned above, a significantly lower 
frequency of the haplotype consisting of these protective G-A alleles was seen in alcohol misusers 
(Table 4). Logistic regression showed that subjects with at least one copy of the rs356219 G allele 
and rs356221 A allele were less likely to have an alcohol misuse phenotype (ORadj = 0.451, df = 1, 
P = 0.004, 95% CI = 0.263–0.774). When examined separately, both alleles were also found to be 
protective (rs356219: ORadj = 0.421, df = 1, P = 0.002, 95% CI = 0.245–0.725; rs356221: ORadj = 
0.452, df = 1, P = 0.009, 95% CI = 0.250–0.819). 
3.4 Determining the Influence of Genotype on α-Synuclein Expression 
 Partitioning the expression data according to each individual‟s SNCA genotype had no effect 
for any of the SNPs individually or in combination. Cases were again separated into groups for 
logistic regression on the basis of the previously established 3'-UTR haplotype (Foroud et al., 2007) 
as well as the 3'-UTR haplotype found in our population. Within the expression cohort, only one 
control individual was predicted to have the haplotype that was associated with cravers, while 
twenty individuals (8 controls, 12 alcohol misusers) were predicted to have the complementary 
haplotype associated with non-cravers. Furthermore, 26 alcohol misusers and 17 control individuals 
had the haplotype found in our study population. There was no significant difference in α-synuclein 
expression of any of the transcripts when compared on this basis (Table 5). 
4. DISCUSSION 
 We measured the expression of three α-synuclein splice variants in the prefrontal cortex of 
human alcohol misusers. The expression of the SNCA-140 and SNCA-112 variants was significantly 
lower in the prefrontal cortex of cirrhotic alcohol misusers compared with controls. Conversely, the 
expression of the SNCA-115 variant, was significantly higher in cirrhotic alcohol misusers 
compared with controls. There was no significant difference in the expression of the SNCA-140, 
SNCA-112 or SNCA-115 variants between uncomplicated alcohol misusers and controls. In previous 
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studies α-synuclein has been shown to be differentially regulated in the prefrontal cortex in 
microarray (Lewohl et al., 2000) and proteomic (Lewohl et al., 2004) studies; however, neither of 
these techniques is definitive for highly homologous transcripts. Neuropathological studies have 
shown that chronic alcohol misuse results in significant brain damage which is exacerbated in 
individuals with concomitant liver cirrhosis (Harper and Kril). This study is the first to report gene 
expression changes of individual splice variants in the brains of human alcohol misusers. However, 
it is not possible to determine whether the changes in α-synuclein expression observed in our study 
are the result of cirrhosis per se, reflect the extent of brain damage observed in cirrhotic alcohol 
misusers, or is the result of greater alcohol exposure in these individuals. 
 α-Synuclein is expressed in response to a number of stimuli, including apoptotic signals, 
oxidative stress, and excitotoxicity, and is dysregulated in neurodegenerative diseases such as 
Parkinson and Alzheimer disease (Sidhu et al., 2004). Our study provides strong evidence that α-
synuclein splice variants are differentially regulated following chronic alcohol misuse and that this 
dysregulation is selective for the pathologically susceptible prefrontal cortex. Previous studies have 
shown that these variants exhibit distinct expression profiles in both healthy brain tissue and in 
neuropathological conditions such as Parkinson disease, Lewy body disease and Alzheimer disease 
(Beyer et al., 2008; Cardo et al., 2014). The functional differences between these splice variants 
remain unclear, however, it is likely that the shorter variants produce a protein with a different 
structure to the wild-type protein which may in turn affect their chaperone activity and aggregation 
properties (Beyer et al., 2008; Bungeroth et al., 2014). 
 α-Synuclein is a negative regulator of dopamine release (Abeliovich et al., 2000; Perez et 
al., 2002). It alters dopamine synthesis via the transcriptional regulation of genes involved in 
dopamine synthesis (Baptista et al., 2003), and influences dopamine re-uptake by the dopamine 
transporter (Wersinger and Sidhu, 2003). Complete or partial knockdown of α-synuclein in 
laboratory animals increases dopamine release (Abeliovich et al., 2000; Yavich et al., 2004), 
reduces dopamine uptake (Fountaine and Wade-Martins, 2007), and sensitizes the brain reward 
system (Oksman et al., 2006). Thus, reduced expression of the SNCA-140 and SNCA-112 variants 
may attenuate dopaminergic neurotransmission in the prefrontal cortex. In turn, this may increase 
the risk of neuronal damage and the inability for neurons to adapt to long-term alcohol exposure 
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(Baptista et al., 2003; Yavich et al., 2004). α-Synuclein has dual roles in neuroprotection and 
neurotoxicity (Seo et al., 2002); the increased expression of SNCA-115 may be one mechanism by 
which neurons adapt to the presence of alcohol. 
 The expression of α-synuclein is modulated by exposure to alcohol and other drugs of 
misuse in both animal models and human subjects. Actively drinking and recently withdrawn 
alcohol misusers have elevated α-synuclein serum levels that correlate with increased craving for 
alcohol (Bonsch et al., 2005a, 2004). Primates that self-administer alcohol have a three-fold higher 
expression of α-synuclein than alcohol-naïve controls (Walker and Grant, 2006). Rats selectively 
bred for high alcohol preference have altered expression of SNCA as a result of a single 
polymorphic variant in its 3'-UTR (Liang et al., 2003). The three splice variants measured in our 
study differ in one key aspect. SNCA-140 and SNCA-112 share the same 3'-UTR although it is 
likely that the length of the 3'-UTR varies between these transcripts. The SNCA-115 variant has a 
unique 3'-UTR coded by part of intron 4. One potential mechanism by which these transcripts may 
be regulated could be through sequence variation in the 3'-UTR of the gene. 
 Thus, we examined the association between eight polymorphisms in the SNCA gene and an 
alcohol misuse phenotype, and the influence of genetic variation in these polymorphisms on the 
expression of α-synuclein splice variants. Allele and genotype frequencies were found to differ 
significantly between alcohol misusers and controls for three of the SNPs: rs356219, rs356221 and 
rs2736995. We performed further analysis to determine if LD existed in our population and found 
strong LD between rs356219 and rs356221. Our results showed that both the A (rs356219) and T 
(rs356221) alleles were „risk‟ alleles for alcohol misuse and that the frequency of haplotype A-T 
was significantly lower in controls, whereas a significantly lower frequency of haplotype G-A was 
seen in alcohol misusers. The G (rs356219) and A (rs356221) alleles that make up the G-A 
haplotype, are both „protective‟ alleles and the frequencies of both these alleles were lower in 
alcohol misusers. We therefore expected to see a higher frequency of the G-A haplotype in controls. 
We did not see evidence of the A and T alleles or haplotype being associated with an alcohol misuse 
phenotype in our population. It might be the case that two risk alleles are not enough to 
significantly increase susceptibility. As these two SNPs have previously been found to be part of 
haplotype block by Foroud and colleagues (2007), perhaps a haplotype consisting of a greater 
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number of risk alleles is required to increase an individual‟s risk of being an alcohol misuser and 
produce a significant odds ratio. However we did find that the G and A alleles as well as the G-A 
haplotype decreased the odds of an individual having an alcohol misuse phenotype. These results 
suggest that individuals with either of these alleles may be protected.  
 The other SNPs that have been reported to be in the same haplotype block (Foroud et al., 
2007), were not in LD in our population. It is possible that single polymorphisms or small 
haplotypes do not have sufficient power to detect association (Foroud et al., 2007). We also made 
comparisons between individuals using both the haplotype found in our population and the three tag 
SNP haplotypes corresponding to those previously published (Foroud et al., 2007). However, we 
did not find evidence of risk alleles that were associated with an alcohol misuse phenotype in our 
population.  
 Although we found no evidence that sequence variation in the 3'-UTR of the gene 
influenced the expression of α-synuclein splice variants, this does not preclude the involvement of 
the 3'-UTR in the regulation of the gene. MiRNAs are known regulators of gene expression that 
exert their influence through interaction with the 3'-UTR. The interactions between miRNAs and 
their target genes can be altered in both a direct and indirect manner, with the potential to enhance 
binding affinity of the miRNA to its target, to eliminate a binding site, to change the structure of the 
3'-UTR and prevent access to the binding site as well as create new, illegitimate binding sites. Thus, 
genetic variation in the 3'-UTR that can modify miRNA binding target sites may lead to changes in 
post-transcriptional regulation of the gene (Chen et al., 2008; Georges et al., 2007). Future studies 
should investigate the miRNA regulation of SNCA to provide further insight into the 
pathophysiology of chronic alcoholism, focusing particularly on the effect of 3'-UTR length and 
genetic variation on miRNA-target interactions and expression of the gene and the consequences 
this has on mediating the pathological effects of chronic alcoholism.  
 This study demonstrates that alcohol differentially alters levels of the individual α-synuclein 
splice variants in the prefrontal cortex of alcohol misusers with cirrhosis of the liver. Although we 
did see significant differences in frequencies for rs356219, rs356221 and rs2736995, and LD 
between rs356219 and rs356221, no significant haplotypes were found to predispose individuals to 
an alcohol misuse phenotype or have an effect on α-synuclein gene expression. However, our 
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results suggest that the rs356219/356221 G-A haplotype may decrease the chance of having an 
alcohol misuse phenotype. Understanding the mechanisms that control α-synuclein expression is 
critical to identifying its role in neurodegeneration and the potential for modulating its expression 
levels in vivo as a therapy for neurodegenerative diseases, including chronic alcohol misuse. 
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FIGURE LEGEND 
Figure 1. A representation of the human α-synuclein gene as in Xia et al. (2001) and adapted from 
(Janeczek and Lewohl, 2013). The exons (Ex) and introns (Int) are represented by the black/grey 
boxes and white boxes respectively. The start (ATG) and stop (TAA) codons have been marked. For 
the purpose of this diagram introns 2 and 4 have been collapsed due to their size, as shown by the 
two diagonal lines. The diagram shows the approximate positions of the eight polymorphisms 
included in this study and the Foroud et al. (2007) study. These polymorphisms have been 
associated with alcohol misuse, alcohol craving or alcohol dependence in previous studies (Agrawal 
et al., 2012; Bonsch et al., 2005b; Clarimon et al., 2007; Foroud et al., 2007; Janeczek et al., 2012). 
Figure 2. Relative mRNA expression levels of the three transcript variants SNCA-140, SNCA-112 
and SNCA-115 in controls, alcohol misuse and cirrhotic-alcohol misuse cases. CT values have 
been converted to 2
-CT values. The expression of SNCA-140 was significantly lower in cirrhotic 
alcohol misusers than in both the controls and uncomplicated alcohol misusers. The expression of 
the SNCA-112 variant was significantly lower in cirrhotic alcohol misusers than in controls only. 
The expression of the SNCA-115 variant was significantly greater in cirrhotic alcohol misusers 
compared with both controls and uncomplicated alcohol misusers. *Significant results (P < 0.05 vs. 
controls). 
Figure 3. A visual presentation created by Haploview v4.2 (Barrett et al., 2005) of the pairwise LD 
found between the eight SNPs in this study. Estimates of LD for each pair are represented by the D′ 
value within the squares, the darker squares indicating strong evidence of LD. Strong LD was found 
between rs356219 and rs356221 (D′ = 0.949; r2 = 0.587). 
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Table 1. Case information - Expression study. 
Group N Age (y) PMI (h) Brain weight (g) 
Control (13 female, 11 male) 24 59.00±2.81 30.58±5.01 1328.96±24.95  
Alcohol misuser (10 female, 15 male) 25 51.75±2.83 30.16±3.40 1339.48±26.03 
Cirrhotic alcohol misuser (6 female, 6 
male) 
12 60.33±4.19 24.26±6.08 1234.50±32.94 
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Table 2: Regression Analysis 
Age at Death   
Combined Cases SNCA-140 F1,59 = 0.064, P = 0.802 
 SNCA-112 F1,59 < 0.001, P = 0.982 
 SNCA-115 F1,59 = 0.887, P = 0.35 
   
Post mortem Interval   
Combined Cases SNCA-140 F1,59 = 0.020, P = 0.888 
 SNCA-112 F1,59 = 0.440, P = 0.509 
 SNCA-115 F1,59 = 3.432, P = 0.07 
   
Brain Weight   
Combined Cases SNCA-140 F1,59 = 10.475, P = 0.002 
 SNCA-112 F1,59 = 4.191, P = 0.045 
 SNCA-115 F1,59 = 10.904, P = 0.002 
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Table 3.  Genotype and allele frequencies for the eight SNCA SNPs and association results. 
  Genotype Freq. N (%)  Allele Freq. N (%) 
SNP Genotype Controls Alcohol misusers χ2  (P) Allele Controls Alcohol misusers χ2 (P) 
rs356168 AA 33 (26.4) 42 (36.5) 1.37 A 141 (56.4) 141 (61.3) 1.19 
 AG 75 (60.0) 57 (49.6) (0.241) G 109 (43.6) 89 (38.7) (0.276) 
 GG 17 (13.6) 16 (13.9)   250  230   
 Total 125  115         
rs356200 AA 31 (25.0) 34 (31.0) 0.37 A 138 (55.6) 128 (58.2) 0.31 
 AG 76 (61.3) 60 (54.5) (0.540) G 110 (44.4) 92 (41.8) (0.580) 
 GG 17 (13.7) 16 (14.5)   248  220   
 Total 124  110         
rs356221 AA 30 (24.4) 20 (17.4) 5.20 A 126 (51.2) 94 (40.9) 5.12 
 AT 66 (53.7) 54 (47.0) (0.023) T 120 (48.8) 136 (59.1) (0.024) 
 TT 27 (21.9) 41 (35.6)   246  230   
 Total 123  115         
rs356219 AA 39 (31.9) 59 (51.8) 9.97 A 142 (58.2) 164 (71.9) 9.75 
 AG 64 (52.5) 46 (40.3) (0.002) G 102 (41.8) 64 (28.1) (0.002) 
 GG 19 (15.6) 9 (7.9)   244  228   
 Total 122  114         
rs7684318 TT 102 (83.6) 86 (88.7) 1.14 T 224 (91.8) 183 (94.3) 1.05 
 TC 20 (16.4) 11 (11.3) (0.287) C 20 (8.2) 11 (5.7) (0.306) 
 CC 0 (0) 0 (0)   244  194   
 Total 122  97         
rs2736990 TT 39 (31.2) 45 (39.5) 1.39 T 140 (56.0) 140 (61.4) 1.43 
 CT 62 (49.6) 50 (43.9) (0.239) C 110 (44.0) 88 (38.6) (0.231) 
 CC 24 (19.2) 19 (16.6)   250  228   
 Total 125  114         
rs2736995 TT 58 (48.0) 73 (64.0) 6.65 T 166 (68.6) 181 (79.4) 7.08 
 TG 50 (41.0) 35 (30.7) (0.010) G 76 (31.4) 47 (20.6) (0.008) 
 GG 13 (11.0) 6 (5.3)   242  228   
 Total 121  114         
rs2301134 TT 33 (26.4) 24 (21.1) 0.88 T 129 (51.6) 108 (47.4) 0.85 
 CT 63 (50.4) 60 (52.6) (0.348) C 121 (48.4) 120 (52.6) (0.355) 
 CC 29 (23.2) 30 (26.3)   250  228   
 Total 125  114         
 
Table
Page 29 of 39
Ac
ce
pte
d M
an
us
cri
pt
Table 4: Association analysis of haplotypes formed by the SNPs: rs356221 and rs356219.  
Haplotype 
Controls 
frequency 
Alcohol 
misusers 
frequency 
Permutated χ2 Permutated P 
AT 0.472 0.590 6.678 0.0265 
GA 0.406 0.284 7.839 0.0143 
AA 0.104 0.125 0.496 0.9380 
*χ2 and P values are based on observations of 10000 permutations to correct for multiple 
testing bias.  
*The frequency of the TG haplotype was less than 1% and therefore excluded from analysis. 
Bold type indicates P < 0.05. 
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Table 5. Influence of SNCA 3′UTR haplotypes on α-synuclein expression.   
*only one individual was predicted to have the haplotype that was associated with cravers 
(Foroud et al., 2007). 
Risk Group Conditions Independent-Samples T test  
Rs356219/rs356221 
Risk Haplotype 
0 = other 
1 = rs356219   A    
   = rs356221   T 
SNCA-140: t(54) = 0.298, P = 0.767  
SNCA-112: t(54) = -0.054, P = 0.958 
SNCA-115: t(54) = -0.291, P = 0.772 
Rs356219/rs356221 
Protective Haplotype 
0 = other 
1 = rs356219   G    
   = rs356221   A 
SNCA-140: t(54) = -1.308, P = 0.196 
SNCA-112: t(54) = -0.728, P = 0.470 
SNCA-115: t(54) = -0.040, P = 0.968 
3 Tag SNP 1 
(Foroud et al., 2007) 
0 = other 
1 = rs7684318 C  
      rs356221   A  
      rs356219   G 
SNCA-140: t(48) = -0.303, P = 0.763 
SNCA-112: t(48) = 0.881, P = 0.383 
SNCA-115: t(48) = 0.875, P = 0.386 
3 Tag SNP 2 
(Foroud et al., 2007) 
0 = other 
1 = rs7684318 T  
      rs356221   A  
      rs356219   A 
SNCA-140: t(54) = -0.698, P = 0.488 
SNCA-112: t(54) = -1.014, P = 0.315 
SNCA-115: t(54) = -1.178, P = 0.244 
3 Tag SNP 3 
(Foroud et al., 2007) 
0 = other 
1 = rs7684318 T  
      rs356221   T  
      rs356219   A 
SNCA-140: t(54) = 0.603, P = 0.549 
SNCA-112: t(54) = 0.521, P = 0.605 
SNCA-115: t(54) = -0.982, P = 0.330 
Extended Haplotype 
Cravers  
(Foroud et al., 2007) 
0 = other 
1 =   rs2736990  T 
        rs356168    G 
        rs356200    G 
        rs7684318  C 
        rs356221    A 
        rs356219    G 
SNCA-140: not applicable* 
SNCA-112: not applicable* 
SNCA-115: not applicable* 
Extended Haplotype 
Non-Cravers 
(Foroud et al., 2007) 
0 = other 
1 =   rs2736990  C 
        rs356168    A 
        rs356200    A 
        rs7684318  T 
        rs356221    T 
        rs356219    A 
SNCA-140: t(48) = 0.734, P = 0.467 
SNCA-112: t(48) = -0.102, P = 0.919 
SNCA-115: t(48) = -0.871, P = 0.392 
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Highlights: 
 The expression of SNCA-140 and SNCA-112 was significantly lower in cirrhotic 
alcohol misusers than in controls 
 The expression of SNCA-115 was significantly greater in cirrhotic alcohol misusers 
than in controls 
 The allele and genotype frequencies for three SNPs (rs356221, rs356219 and 
rs2736995) differed significantly between alcohol misusers and controls 
 Two SNPs, rs356221 and rs356219, were in high linkage disequilibrium  
 There was no increased risk of alcoholism associated with specific genotypes or 
haplotypes in our population 
 Results suggest that the rs356219/356221 G-A haplotype may decrease the chance of 
having an alcohol misuse phenotype 
 Sequence variation in the 3'-UTR of the gene did not affect the expression of α-
synuclein splice variants 
 SNPs were not significantly associated with α-synuclein gene expression in our 
population 
 
 
*Highlights (for review)
